Format

Send to

Choose Destination
Nat Rev Cancer. 2007 May;7(5):389-97. doi: 10.1038/nrc2127. Epub 2007 Apr 19.

Insights from transgenic mouse models of ERBB2-induced breast cancer.

Author information

1
Departments of Medicine and Biochemistry, McGill University, Montreal, Quebec, Canada.

Abstract

One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.

PMID:
17446858
DOI:
10.1038/nrc2127
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center